Clinical Trial: A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07221162) titled 'A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes' on Oct. 23.

Brief Summary: This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of Boost-2867, given intramuscular (IM) with or without adjuvant or intranasal (IN) without adjuvant, as a booster dose to previously vaccinated healthy adults. Each of the six study sites will be assigned to enroll either only participants who will receive IM administration (3 sites) or only participants who will receive IN administration (3 sites); no site will administer both IM and IN study product administrations. Wit...